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Abstract
Background: Sub-Saharan Africa (SSA) has confronted decades of the HIV epidemic with substantial improvements
in access to life-saving antiretroviral therapy (ART). Now, with improved survival, people living with HIV (PLWH) are
at increased risk for non-communicable diseases (NCDs), including atherosclerotic cardiovascular disease (CVD). We
assessed the existing literature regarding the association of CVD outcomes and HIV in SSA.
Methods: We used the PRISMA guidelines to perform a systematic review of the published literature regarding the
association of CVD and HIV in SSA with a focus on CVD surrogate and clinical outcomes in PLWH.
Results: From January 2000 until March 2017, 31 articles were published regarding CVD outcomes among PLWH in
SSA. Data from surrogate CVD outcomes (n = 13) suggest an increased risk of CVD events among PLWH in SSA.
Although acute coronary syndrome is reported infrequently in SSA among PLWH, limited data from five studies
suggest extensive thrombus and hypercoagulability as contributing factors. Additional studies suggest an increased
risk of stroke among PLWH (n = 13); however, most data are from immunosuppressed ART-naïve PLWH and thus
are potentially confounded by the possibility of central nervous system infections.
Conclusions: Given ongoing gaps in our current understanding of CVD and other NCDs in PLWH in SSA, it is
imperative to ascertain the burden of CVD outcomes, and to examine strategies for intervention and best practices
to enhance the health of this vulnerable population.
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Background
With more than 26 million people living with human im-
munodeficiency virus (PLWH) in sub-Saharan Africa
(SSA), the daunting immediacy of health needs has neces-
sitated expanding infrastructure to provide care for HIV
infection [1]. As the beneficial effects of antiretroviral
therapy (ART) are increasingly apparent [2], attention has
now shifted to expanding this growing healthcare infra-
structure to also encompass chronic care for non-
infectious, highly prevalent co-morbidities [3, 4].
Non-communicable diseases (NCDs), specifically
cardiovascular disease (CVD), increasingly affect the
general population in SSA [5–7]. The effects of
urbanization and increased life expectancy have been
linked to an increased prevalence of traditional CVD risk
factors, including changes in diet and exercise patterns
[8], although CVD mortality has decreased in SSA over
the past few decades [9, 10]. Concerns regarding the
potential impact of CVD in SSA have focused appropri-
ate and necessary attention on its diagnosis, treatment,
and prevention [11, 12], and disparities in CVD preven-
tion and treatment across SSA have been highly
publicized [12–14]. Interventions in prevention, screen-
ing, and treatment have been shown to be effective and
cost-effective among the general population [15, 16].
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PLWH are at increased risk for CVD [17, 18], and a
synergistic intersection of these two distinct epidemics
may emerge in SSA [11, 19]. As access to ART expands,
more PLWH are living past 50 years of age [20, 21] and
face an increased risk of CVD due to traditional CVD
risk factors alone [22]. The additional impact of HIV
infection with its associated inflammation and
prothrombotic state may further increase CVD risk.
Limited data are available regarding optimal methods for
CVD risk factor screening, primary and secondary pre-
vention, risk stratification, outcomes, and management
in PLWH living in SSA [23, 24]. Now is the time to
anticipate and consider this challenge in the face of ris-
ing multimorbidity due to NCDs and chronic infectious
diseases [25].
To complement previously published reviews of CVD
among PLWH in SSA [26–33], we provide a systematic
review and qualitative summary of the existing primary
literature regarding the association of CVD and HIV in
SSA with a focused emphasis on CVD surrogate and
clinical outcomes. We identify current gaps in know-
ledge, focusing on the need for additional outcomes
data, implementation strategies, and best practices for
risk factor modification and treatment.
Methods
Search strategy
This systematic review of CVD surrogate and clinical
outcomes in PLWH in SSA was conducted according to
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines (Fig. 1) [34]. We identified
articles published from January 2000 to March 2017 through
searches in PubMed that included Medical Subject Headings
(MeSH) terms, “Africa” and “HIV,” as well as any of the fol-
lowing terms: “cardiovascular disease,” “cardiometabolic,”
“metabolic syndrome,” “myocardial infarction,” “acute coron-
ary syndrome,” “dyslipidemia,” “diabetes,” “dysglycemia,”
“hypertension,” “surrogate marker,” “cIMT,” “pulse wave
velocity,” “aortic augmentation index,” “ankle-brachial index,”
“endothelial activation,” “radial tonometry,” “flow-mediated
dilation,” or “stroke.” We included additional articles found
in review of bibliographies or suggested by co-authors based
on their relevance to the selected search terms. The full list
of search terms is reported in Additional file 1.
Study selection
We selected relevant articles in a stepwise manner. Two
co-authors (EPH and EBM) independently screened arti-
cles by title to ensure that the analysis included articles
regarding PLWH, CVD, and sub-Saharan Africa. We
next reviewed the selected abstracts, using the following
inclusion criteria: study population without children or
pregnant women; primary quantitative data; specific CVD
risk factors or outcomes; assessment of an association
between CVD and HIV; English written text. Last, we
assessed the remaining full-text articles for eligibility and
determined which studies would be included in qualitative
synthesis.
Data extraction
Two co-authors (EPH and MM) extracted data for quali-
tative synthesis, including location, year of study, study
design, sample size, population age (in years), and ART
status, and summarized the main findings of eligible
analyses. We did not perform quantitative synthesis
because published study data included diverse populations




Full-text articles selected for eligibility were further
separated into CVD risk factors (n = 123), biomarkers of
immune status and endothelial activation (n = 12), and
CVD outcomes (n = 31) (Fig. 2). Studies categorized as
CVD risk factors or biomarkers of immune status and
endothelial activation are reported in an additional
reference list (see Additional file 2). The eligible 31 ana-
lyses evaluated the impact of HIV status on surrogate
CVD outcomes (n = 13), acute coronary syndrome
(ACS) (n = 5), and stroke (n = 13) for inclusion in quali-
tative synthesis and detailed data extraction.
CVD risk factors
Traditional CVD risk factors are prevalent in SSA
among the general population and include hypertension
(6-22%) [35–37], dyslipidemia (5–70%) [38], diabetes
(1-12%) [35, 39], and smoking (males 15%, females 0.6%)
[40, 41]. Despite these high prevalence estimates, almost
67% of diabetics and 50% of hypertensives are thought
to be unaware of their status [14, 42]. Tobacco use varies
widely in different regions and is likely under-reported,
particularly among women [40].
Among PLWH in the US and Europe, traditional CVD
risk factors are highly prevalent, even when accounting
for age [43]. Hypertension is associated with CVD risk
in PLWH [44], and an important interplay also occurs
between lipid indices, HIV, chronic inflammation, and
antiretroviral medications [45–47]. PLWH are at risk for
impaired glucose tolerance (IGT) and for diabetes [48].
Smoking is at least twice as prevalent in PLWH in the
US [49] and has a greater impact on overall mortality
than HIV itself in the setting of available ART [50].
Considerably less is known about the determinants
and impact of CVD risk factors among PLWH in
SSA. The association of hypertension with higher
CD4 counts and older age suggests that hypertension
may be a substantial problem among PLWH in SSA
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as they age on ART [22, 51–54]. Wide ranges in
prevalence of IGT (16-24%) [55–58] and diabetes
(1-18%) [58–64] are reported in PLWH in SSA. Total
cholesterol, low-density lipoprotein (LDL), and high-
density lipoprotein (HDL) all rise following ART
initiation, yet a relatively smaller increase in HDL
results in a pro-atherosclerosis lipid profile [65–71].
Smoking is a public health concern in SSA, yet the
role of HIV with regards to smoking rates in this
setting remains unclear. Some cohorts demonstrate an in-
creased prevalence of smoking compared with the general
public in the region (23% vs 16%) [72, 73], while others
show decreased smoking rates among PLWH (48% vs
31%) [74] or no difference [69, 75–78].
Chronic inflammation plays a role in the develop-
ment of atherosclerotic CVD among PLWH, and
evidence is mounting for the contribution of viremia
and immunosuppression towards the premature
development of CVD [79, 80]. Although several SSA
studies demonstrated immune activation among both
ART-naïve and –experienced PLWH [78, 81–84], a
South African study focused on older PLWH
(≥50 years) demonstrated a reduction in inflammatory
markers (i.e., CRP, IL-1, IL-6, and TNF-α) after ART-
Fig. 1 Flow diagram for the selection of studies. We followed PRISMA guidelines for screening articles in the systematic review. We identified
articles via a systematic search of the PubMed database and derived additional records from reference lists of previously identified articles or co-
author input. Articles were screened first by title, then by abstract, and finally on explicit inclusion/exclusion criteria. Full-text articles considered
eligible for inclusion were categorized based on emphasis of CVD risk factors, biomarkers of immune status and endothelial activation, surrogate
CVD outcomes, acute coronary syndrome, and stroke
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initiation [85]. Evaluating the role of immune activa-
tion and cardiovascular risk in a cohort of PLWH on
ART in southwestern Uganda, lower absolute levels of
sCD14 and IL-6, markers of monocyte activation and
generalized inflammation, were found to be signifi-
cantly associated with lower future carotid intima
media thickness (cIMT), a marker of preclinical
atherosclerosis, after adjusting for traditional CVD
risk factors [86]. Several studies in SSA have also
consistently demonstrated that PLWH experience
excess endothelial activation [78, 87], which persists
even after the introduction of ART [82]. Given the
potential impact of chronic inflammation on PLWH
in SSA and possible concomitant mediators of inflam-
mation from other infections endemic to the region
[88], further research into the pathogenesis of athero-
sclerotic CVD among PLWH in SSA will be valuable
and may offer additional insights into molecular
markers, predictive tests, and treatment options.
Patterns of screening and diagnosis of CVD risk
factors in SSA may differ by HIV status. PLWH are less
likely to be asked about CVD risk factors at routine
clinical visits compared with HIV-uninfected groups
[89]. However, when CVD risk factors are actively
assessed, PLWH on ART may be more likely to be diag-
nosed with hypertension or diabetes than patients with
unknown HIV status. In a South African study using
pharmacy records, for instance, hypertension was the
most common second diagnosis among PLWH on ART,
making it more common than tuberculosis (TB) [25].
PLWH may also be more likely to have multiple CVD
risk factors, thus increasing their overall risk of CVD
outcomes. Among patients on ART for more than
34 months in Cameroon, 61% had one CVD risk factor,
and 18% had two or more CVD risk factors [90]. Among
virologically suppressed PLWH ages 40-50 in Botswana,
the American Heart Association (AHA)/American
College of Cardiology (ACC) risk equation demonstrated
elevated risk of CVD outcomes, which correlated with
cIMT measurements [91]. However, only 3.6% of
patients who were actively screened for CVD risk factors
in a South African study were found to have more than
a 10% risk of a CVD event in the next 10 years, using a
risk stratification tool from the World Health
Organization and International Society of Hypertension
[63]. Strategies to estimate CVD risk among PLWH have
not been formally assessed in SSA, and accurate risk
prediction algorithms will be important to guide
preventive care.
CVD outcomes
Although data are increasingly available regarding CVD
risk factors among PLWH in SSA, data on CVD out-
comes remain scarce (Fig. 2).
Surrogate CVD outcomes
Assessment of surrogate CVD outcomes (e.g., cIMT, pulse
wave velocity (PWV), aortic augmentation index (AI),
ankle-brachial index (ABI), flow-mediated dilation (FMD),




























Acute coronary syndrome (n=5)
Surrogate CVD outcomes (n=13)
Stroke (n=13)
Biomarkers of immune status and
endothelial activation (n=12)
CVD Risk factors (n=123)
Year of Publication
Fig. 2 Publication year for studies on HIV and CVD risk factors and outcomes in sub-Saharan Africa. Full-text articles were stratified by year of
publication and description of CVD risk factors, biomarkers of immune status and endothelial activation, surrogate CVD outcomes, acute coronary
syndrome, or stroke. Of the 166 studies assessed in this review, the majority (n = 102) were published between 2013 and 2016. Only 3 months of
2017 publications were included
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increased risk of CVD events among PLWH in SSA
(Table 1). Although the surrogate outcomes studied are
diverse and reflect discrete vascular functions, the
majority of studies showed increased atherosclerosis
among PLWH, either versus controls or in relation to
HIV disease duration or treatment status. Although some
studies demonstrate no evidence for increased athero-
sclerosis among PLWH [78, 92], most studies show early
subclinical atherosclerosis by surrogate CVD outcomes
[81, 93–98]. A large Ugandan study demonstrated subclin-
ical atherosclerosis via cIMT in 18% of PLWH attending
clinic with higher risk among ART-experienced or older
patients with elevated body mass index (BMI) or LDL
[95]. A second study in Uganda diagnosed arterial stiffness
by ABI in 33% (19%) of male (female) PLWH on
ART for 7 years, which was twice the prevalence
compared to age- and sex-matched HIV-uninfected
controls after adjustment for traditional CVD risk
factors [97]. A cross-sectional study from South
Africa demonstrated that 12% of PLWH (median age
41 years, 69% female) had subclinical atherosclerosis
by cIMT that was associated with traditional but not
HIV-related factors [99]. Studies comparing surrogate
CVD outcomes in PLWH versus comparator HIV-
uninfected groups will further elucidate the role that
HIV could play in the development of atherosclerosis.
The long-term implications of these altered vascular
indices remain unknown among PLWH in SSA and
warrant further investigation.
Acute coronary syndrome
Acute coronary syndrome (ACS) is reported relatively
infrequently in SSA [11, 27]. Events may be underre-
ported due to “silent” myocardial infarctions, limited
access to diagnostic tests, and lack of patient and health-
care provider awareness. However, a recent study shows
that more than 5% of cardiac hospitalizations are attrib-
utable to ACS in South Africa [100]. With increasing life
expectancy and a growing burden of CVD risk factors,
the incidence of ACS and subsequent morbidities may
rise in SSA.
Specifically among PLWH living in SSA, ACS is not re-
ported frequently, and no studies have investigated ACS
incidence in PLWH relative to control patients [24, 27]. In
a large cohort study in Soweto, South Africa following
5328 new cases of heart disease, ACS was described in
only 3% of the 518 cases of cardiac hospitalization among
PLWH (although HIV testing was performed only when
“clinically indicated”) (Table 2) [24]. The presentation of
ACS was further examined in a separate study from the
same population in which all patients with ACS were
tested for HIV. In comparison to HIV-uninfected controls,
30 HIV-infected cases were younger and more likely to
have a history of smoking but less likely to have traditional
CVD risk factors such as diabetes, hypertension, and
dyslipidemia [101]. Angiographic features among the
HIV-infected cases revealed acute thrombus with a low
burden of underlying atherosclerotic plaque, consistent
with US studies showing fewer involved vessels and a
greater relative burden of inflammatory plaque [102]. A
follow-up study of this same study population demon-
strated a greater prevalence of coagulopathy among the
PLWH who presented with myocardial infarction, specif-
ically elevated protein C levels [103]; anti-phospholipid
antibodies were not found to be associated with ACS
among PLWH [104].
PLWH may be at higher risk for coronary artery dis-
ease than suggested by traditional CVD risk factors
alone, given data on post-operative cardiovascular mor-
bidity and mortality. In a South African cohort of 255
patients undergoing vascular surgery, 32% were HIV-in-
fected of whom 23% were on ART [105]. When com-
pared to vascular surgery patients confirmed to be HIV-
uninfected, PLWH were equally as likely to have myo-
cardial infarction as measured by troponin elevations on
post-operative day three or to experience 30-day mortal-
ity. PLWH were less likely to have known traditional
CVD risk factors and were less likely to be on cardiovas-
cular medications; it is not known if the prevalence of
traditional CVD risk factors was lower among PLWH or
if they were less likely to have been previously screened
for these diseases.
Stroke
Stroke is a substantial problem in the general population
in SSA and is associated with high rates of mortality,
morbidity, and post-stroke disability [13, 106–108]. An
association between HIV infection and stroke has been
described in high-income countries [109–111]; data
emerging from SSA also suggest a high prevalence of
stroke among PLWH. Relative to ACS, data regarding
stroke among PLWH in SSA are more extensive, which
may be due to the more readily recognizable symptoms
of stroke that are likely to result in presentation to med-
ical attention, as well as the high prevalence of hyperten-
sion in SSA. Three distinct study designs have been used
to investigate an association of stroke and HIV in SSA:
1) comparisons of PLWH and HIV-uninfected patients
who present with stroke; 2) comparisons of stroke pa-
tients with population controls, evaluating for HIV status
in both groups 3) assessment of cohorts of PLWH, some
of whom have had stroke (Table 3).
HIV infection is frequently reported among patients
enrolled in studies that assessed new stroke patients.
Almost 3% of all inpatient admissions were due to stroke
in a Malawi cohort comprising 70% PLWH [112]. A
prospective cohort of young stroke patients (<46 years)
admitted to a South African stroke referral hospital
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demonstrated HIV infection in 23%, more than twice
the population’s HIV prevalence (11%) [113]. In a
hospital-based South African cohort study of PLWH
with stroke, 57% of patients presented with stroke as
their initial presentation of HIV [114]. Although morbid-
ity and mortality remain very high among patients after
stroke in SSA, outcomes of PLWH versus the general
population post-stroke did not differ substantially in
terms of case-fatality rates or disabilities [112, 115].
When comparing stroke patients with and without
HIV, some studies found no differences in risk factors
or outcomes [116]. Other studies found that PLWH
with stroke were more likely to be younger and have
fewer traditional CVD risk factors than stroke
patients without HIV [112, 113, 115, 117]. Such re-
sults suggest a possible role of HIV infection itself or
other nontraditional risk factors in conferring stroke
risk among PLWH in this setting. However, such
studies have predominantly assessed patients who are
ART-naïve and often recently diagnosed with HIV;
these patients are more likely to be immunosup-
pressed and at increased risk for opportunistic infec-
tions which could impact the central nervous system.
Infectious etiologies of stroke are more common in
PLWH, and rigorous diagnostic workup in one study
revealed infectious causes in 23% of PLWH compared
to none of the HIV-uninfected [112]. Other studies
found a similarly high probability of infectious
etiology for stroke when comprehensive diagnostic
testing was performed [113, 114].
Two studies that used a case-control study design to
compare stroke patients with non-stroke controls from
the community demonstrated an independent associ-
ation between HIV and stroke, as well as an association
between stroke and traditional CVD risk factors [118,
119]. In one study, all PLWH were ART-naïve [118]; in
the other study, an association between the timing of
ART initiation (within the past 6 months) and stroke
was significant, suggesting a possible role for immune
reconstitution syndrome [119]. Neither study outlined a
thorough diagnostic workup for other infectious causes
of stroke, which could be an important, unmeasured
confounder.
Data regarding stroke in PLWH on ART for more than
a year and therefore at reduced risk for infectious etiolo-
gies will be essential to extend our understanding of
CVD in PLWH in SSA.
Discussion
Summary of literature and current knowledge gaps
Although our review of the published literature under-
scores the increasing availability of data on this topic
(Fig. 2), substantial limitations in existing data remain.
Published data still frequently include small sample sizes
and are likely under-powered to detect differences.
Additionally, the patient populations are frequently
younger than 50 years and therefore do not reflect the
aging of the epidemic, and many studies do not evaluate
the impact of socio-economic status on CVD risk factors
and outcomes. Many studies continue to present data on
mixed populations of ART-naïve and ART-experienced
patients so that the impact of immunosuppression and
longitudinal treatment with ART cannot be assessed.
Moreover, in case-control studies that include an HIV-
uninfected control group, patients are rarely proactively
tested for HIV, so the control group likely includes a
mixed population of people living with and without
HIV. Studies that include ART-naïve PLWH often do
not include a thorough diagnostic workup for infectious
etiologies of stroke. CVD outcomes, particularly ACS,
peripheral arterial disease, and venous thromboembolic
disease, are infrequently identified and reported, so the
impact of any increasing prevalence of CVD risk factors
remains uncertain. Most studies report cross-sectional
data, which do not capture risks, exposures, and
outcomes over time. Case-control studies often include
unmeasured confounders, including infectious co-
morbidities such as tuberculosis or syphilis. Last, data are
often from clinical cohorts or trials, which might not be
representative of PLWH engaged in care in large public
health programs.
Larger cohort studies among PLWH and HIV-
uninfected patients in SSA during the ART era will clarify
the incidence, prevalence, and attributable morbidity and
mortality of CVD risk factors and outcomes in these
populations. Focused investigation regarding possible in-
teractions of traditional CVD risk factors with HIV infec-
tion, ART, and chronic inflammation can elucidate
potential pathophysiologic mechanisms for further com-
parison with data from the US and Europe to guide pre-
vention and management strategies. Innovative models of
integrated care, which are appropriate and scalable for en-
hanced CVD risk management, should be extensively
studied in SSA. Such models should leverage successful
HIV programs, where feasible.
Prospective ascertainment of best practices for CVD
risk factor screening and CVD management in SSA will
identify future interventions for PLWH. Abundant
opportunities for CVD risk factor screening exist for
PLWH given frequent interactions with community
testing campaigns and clinical care [120, 121], but subse-
quent linkage to and retention in clinical care after
diagnosis is essential in order to optimize both HIV and
CVD outcomes [36]. The identification of optimal ART,
anti-hypertensive, lipid, and diabetes management strategies
for PLWH is needed, as well as implementation of effective
methods of lifestyle modification, nutrition education, smok-
ing cessation, and expansion of opportunities to exercise.
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The Randomized Trial to Prevent Vascular Events in HIV
(REPRIEVE) trial, with its sites in SSA, will provide new data
on CVD risk reduction in this setting [122].
Policy implications
As more PLWH are successfully linked to clinical care
and treated with ART, attention must turn to maintaining
their restored health in order to realize the full health ben-
efits of ART. The existing and expanding health care in-
frastructure developed for HIV presents an opportunity to
incorporate additional preventative interventions for
chronic disease complications to decrease morbidity and
improve quality of life for PLWH.
Some argue that integration of non-HIV medical ser-
vices with HIV clinical care could decrease quality of
care and dilute the effectiveness of current HIV pro-
grams. Concerns that investment in HIV care has
detracted from investments in other forms of health
care, such as immunizations [123], have tempered en-
thusiasm for expanding HIV health systems to include
additional health care directives.
However, the potential benefits of an integrated ap-
proach to medical care for PLWH in SSA and other
resource-limited settings could be profound, and support
for this approach has been fast-growing [20, 124–126].
The established and expanding HIV infrastructure could
be an ideal foundation on which to build additional inter-
ventions and management strategies for other chronic dis-
eases [29, 127]. An emphasis on HIV as a chronic disease
that requires life-long management has also influenced
the paradigm of care [128–130] and encourages the use of
current HIV infrastructure as a platform for management
of chronic non-infectious co-morbidities. In regions where
primary care services are already more established, exist-
ing clinical services could alternatively serve as a platform
for decentralizing HIV care and integrating with existing
NCD prevention and management efforts [131].
Conclusions
The limited data available from PLWH in SSA regarding
atherosclerotic CVD outcomes suggests an increased
risk of early atherosclerosis and stroke. Given ongoing
gaps in our current understanding of CVD in PLWH in
SSA, now is the time to advance targeted research prior-
ities and determine the burden of CVD outcomes, strat-
egies for intervention, and best practices to enhance the
health of this vulnerable population.
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